

Australia

Patents Act 1990

NOTICE OF ENTITLEMENT

I, John Gordon Hinde, of Spruson & Ferguson, St Martins Tower, 31 Market Street, Sydney, New South Wales 2000, Australia, being the patent attorney for the Applicant(s)/Nominated Person(s) in respect of an application entitled:

Homobifunctional Agents for Coupling Enzymes and the Like  
to Antibodies and the Like

state the following:-

The Applicant(s)/Nominated Person(s) has/have entitlement from the actual inventor(s) as follows:-

The Applicant(s)/Nominated Person(s) is/are the assignee(s) of the actual inventor(s).

The Applicant(s)/Nominated Person(s) is/are entitled to rely on the application(s) listed in the Declaration under Article 8 of the PCT as follows:

The Applicant(s)/Nominated Person(s) is/are the assignee(s) of the basic applicant(s).

The basic application(s) listed on the Declaration under Article 8 of the PCT is/are the application(s) first made in a Convention country in respect of the invention.

DATED this Twentieth day of April 1993

.....  
John Gordon Hinde

IRN: 238462

INSTR CODE: 50000

5

KRS/665P



AU9189059

**(12) PATENT ABRIDGMENT (11) Document No. AU-B-89059/91**  
**(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 657284**

(54) Title  
 HOMOBIFUNCTIONAL AGENTS FOR COUPLING ENZYMES AND THE LIKE TO ANTIBODIES AND THE LIKE

(51)<sup>5</sup> International Patent Classification(s)  
 C07D 207/452 C07C 243/34 C07D 207/46 C12Q 001/42  
 G01N 033/82 G01N 033/535 G01N 033/566

(21) Application No. : 89059/91 (22) Application Date : 18.10.91

(87) PCT Publication Number : WO92/07268

(30) Priority Data

(31) Number (32) Date (33) Country  
 600795 22.10.90 US UNITED STATES OF AMERICA

(43) Publication Date : 20.05.92

(44) Publication Date of Accepted Application : 09.03.95

(71) Applicant(s)  
 ABBOTT LABORATORIES


(72) Inventor(s)  
 CHRISTOPHER BIENIARZ; CHRISTOPHER WELCH

(74) Attorney or Agent  
 SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001

(56) Prior Art Documents  
 AU 626809 24411/88 C07D 207/452  
 AU 624686 51231/90 C07D 207/46  
 AU 620417 37684/89 C07D 207/452


(57) Claim

1. A coupling agent having the formula




where

Z<sub>1</sub> and Z<sub>2</sub> are the same when they are



Z<sub>1</sub> and Z<sub>2</sub> are the same or different when they are



(11) AU-B-89059/91  
 (10) 657284

-2-


k, m and n are integers from 1 to 10;

X is an alkylene group, a cycloalkylene group, an alkylcycloalkylene group, a bivalent carbocyclic aromatic group, or an aminoalkylene group;

R and R' can be the same or different, and each is a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> straight chain aminoalkylene; and


R'' is a C<sub>2</sub>-C<sub>10</sub> alkylene or a C<sub>5</sub>-C<sub>20</sub> cycloalkylene or alkylcycloalkylene.

2. A coupling agent having the formula



where

Z<sub>3</sub> and Z<sub>4</sub> are the same or different and are



k and m are integers from 0 to 10;


n is an integer from 1 to 10;

X is an alkylene group, a cycloalkylene group, an alkyl cycloalkylene group, a bivalent carbocyclic aromatic group;

R and R' can be the same or different, and each is a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> straight chain aminoalkylene; and

R'' is a C<sub>2</sub>-C<sub>10</sub> alkylene or a C<sub>5</sub>-C<sub>20</sub> cycloalkylene or alkylcycloalkylene.

3. A coupling agent having the formula




where

x and n are integers from 1 to 10;

y is an integer from 2 to 10; and

Z<sub>5</sub> and Z<sub>6</sub> are the same or different and are



wherein R'' is a C<sub>2</sub>-C<sub>10</sub> alkylene or a C<sub>5</sub>-C<sub>20</sub> cycloalkylene or alkylcycloalkylene. /3

(11) AU-B-89059/91

- 3 -

(10) 657284

16. A method for conducting an assay for cobalamins, said method comprising denaturing a test sample, adding to the denatured test sample a conjugate wherein microparticles are conjugated to intrinsic factor purified by separation of R-proteins therefrom to such an extent that the purified material contains less than 0.004 percent cross reactivity with cobinamides by a moiety from a coupling agent as claimed in any one of claims 1-10, incubating the denatured test sample containing the conjugate, depositing the incubated composition on a separation material which retains the intrinsic factor/microparticle conjugate, washing the separation material surface to remove unbound B12, adding a conjugate of an enzyme and a specific binding member for the purified intrinsic factor to the separation material to bind free intrinsic factor sites, washing the separation material, adding a substrate indicator which reacts with the enzyme to produce a signal or to produce a reaction product which can be caused to produce a signal, and measuring the signal produced by reaction between the enzyme and the indicator or causing the product of the reaction between the enzyme and the indicator to produce a signal and measuring the signal.

OPI DATE 20/05/92

APPLN. ID

89059 / 91




IN AOJP DATE 25/06/92

PCT NUMBER PCT/US91/07640

ATION TREATY (PCT)

<p>(51) International Patent Classification<sup>5</sup> : G01N 33/567, C07D 207/40 C07D 207/452, 207/46, 207/444 C07C 243/24</p>	A1	<p>(11) International Publication Number: WO 92/07268 (43) International Publication Date: 30 April 1992 (30.04.92)</p>
<p>(21) International Application Number: PCT/US91/07640 (22) International Filing Date: 18 October 1991 (18.10.91) (30) Priority data: 600,795 22 October 1990 (22.10.90) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: BIENIARZ, Christopher ; 718 Old Trail, Highland Park, IL 60035 (US). WELCH, Christopher ; 910 E. Oregon Street, Urbana, IL 60801 (US). (74) Agents: GORMAN, Edward, H., Jr. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent).  Published With international search report.  657284</p>

(54) Title: HOMOBIFUNCTIONAL AGENTS FOR COUPLING ENZYMES AND THE LIKE TO ANTIBODIES AND THE LIKE



(57) Abstract

A coupling agent useful in conducting immunoassays, particularly assays for B12, is disclosed. The coupling agent has formula (I) where Z and Z' can be the same or different, and each is H<sub>2</sub>NHN, ICH<sub>2</sub>, (a) or (b); k, m and n are integers from 1 to 10, X is an alkylene group, a cycloalkylene group, an alkylcycloalkylene group, a bivalent aromatic group, or an aminoalkylene group, R and R' can be the same or different, and each is a substituted or unsubstituted aminoalkylene group having from 1 to 10 carbon atoms or a cycloalkylene or alkylcycloalkylene group having from 5 to 20 carbon atoms. Z and Z' are the same except that they can be the same or different when both are (c). A method for purifying an aqueous intrinsic factor solution which contains R-protein is disclosed. The method involves adding to the intrinsic factor solution an amount of cobinamide sufficient to bind substantially all of the R-protein in the solution and an amount of an intrinsic factor affinity resin sufficient to bind the intrinsic factor in the solution, washing the bound cobinamide and the R-protein from the resin, eluting the intrinsic factor from the resin, and dialyzing the eluted intrinsic factor. The purified intrinsic factor can contain less than 0.004 percent cross reactivity with cobinamides, and at least 95 percent of the proteins in the purified material can bind cobalamins. A conjugate where microparticles and the purified intrinsic factor are conjugated by a moiety from one of the foregoing coupling agents is also disclosed, as is a kit for conducting an assay for cobalamins which includes the conjugate of microparticles and purified intrinsic factor. A method for conducting an assay for cobalamins, which method involves the use of the conjugate of microparticles and purified intrinsic factor is also disclosed.

TITLE  
**HOMOBIFUNCTIONAL AGENTS FOR COUPLING ENZYMES  
AND THE LIKE TO ANTIBODIES AND THE LIKE**

**FIELD OF THE INVENTION**

5 This invention relates to homobifunctional agents for coupling enzymes and the like to antibodies and the like, and to enzymes and the like coupled to antibodies and the like by the homobifunctional agents. Specifically, the homobifunctional agents can be used to couple antibodies, cells, enzymes, coenzymes, proteins, haptens and small molecules to enzymes, coenzymes, antibodies, proteins, solid phases, polymers and liposomes, and the coupled compound, sometimes herein called a "conjugate",  
10 can be an antibody, a cell, an enzyme, a coenzyme, a protein, a hapten or a small molecule coupled to an enzyme, a coenzyme, an antibody, a protein, a solid phase, a polymer or a liposome.

**BACKGROUND OF THE INVENTION**

The following discussion of immunoassays and definitions of terms often used with respect to immunoassays are set forth herein as background to facilitate the understanding of the disclosure and claims  
15 hereof.

The term "analyte" refers to the protein, which may be, but is not necessarily, an antibody, to be detected.

The term "test sample" typically refers to a sample of body fluid such as plasma, serum, ascites, lymphatic fluids, cerebral spinal fluid, nipple fluid discharge, urine and other body fluids that may contain  
20 the analyte of interest. Optionally, the test sample can be diluted in a suitable diluent buffer, such as phosphate buffered saline with serum components, to provide a sample volume that is required by the particular immunoassay.

The term "specific binding member" refers to a member of a specific binding pair, i.e., two different molecules wherein one of the molecules through chemical or physical means specifically binds to the  
25 second molecule. In addition to antigen and antibody specific binding pairs such as the allergen and antibody pair, other specific binding pairs include biotin and avidin, carbohydrates and lectins, complementary nucleotide sequences, complementary peptide sequences, effector and receptor molecules, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, a peptide sequence and an antibody specific for the sequence protein, polymeric acids and bases, dyes and protein binders, peptides and specific  
30 protein binders (e.g., ribonuclease, S-peptide and ribonuclease S-protein), and the like. Furthermore, specific binding pairs can include members that are analogs of the original specific binding member, for example an analyte-analog. If the specific binding member is an immunoreactant it can be, for example, an antibody, antigen, hapten, or complex thereof. If an antibody is used, it can be a monoclonal or polyclonal antibody, a recombinant protein or antibody, a mixture or mixtures or a fragment or fragments  
35 thereof, as well as a mixture of an antibody and other specific binding members. The details of the preparation of such antibodies and their suitability for use as specific binding members are well-known to those skilled-in-the-art.

The term "indicator reagent" refers to an assay reagent comprising a detectable label directly or indirectly attached to a specific binding member which is capable of directly or indirectly binding to the analyte and thereby indicating the presence, absence or amount of the analyte in a test sample. A variety of different indicator reagents can be formed by varying either the label or the specific binding member. In general, the indicator reagent is detected after it has formed a complex with either the analyte or a complementary specific binding member, but the unbound indicator reagent can also be detected.

The term "label" refers to any substance which is attached to a specific binding member and which is capable of producing a signal that is detectable by visual or instrumental means. Labels can include chromogens; catalysts; fluorescent compounds; chemiluminescent compounds; radioactive isotopes; direct visual labels including colloidal metallic and non-metallic particles, dye particles, enzymes or substrates, or organic polymer latex particles; liposomes or other vesicles containing signal producing substances; and the like.

Many enzymes suitable for use as labels are disclosed in U. S. Patent No. 4,275,149, columns 19-23, herein incorporated by reference. For example, an enzyme/substrate signal producing system useful with 4-methylumbelliferyl phosphate is the enzyme alkaline phosphatase. If horse-radish peroxidase is used, o-Phenylenediamine is added as an enzyme substrate to form a colored product which can be detected and/or measured visually or instrumentally.

In an alternative signal producing system, the label can be a fluorescent compound where no enzymatic manipulation of the label is required to produce a detectable signal. Fluorescent molecules such as fluorescein, coumarin, phycobiliprotein, rhodamine and their derivatives and analogs are suitable for use as labels in this system.

Another class of labels includes the visually detectable, colored particles which enable a direct colored readout of the presence or concentration of the analyte in the test sample without the need for using additional signal producing reagents. Materials for use as such particles include colloidal metals, such as gold, and dye particles as disclosed in U.S. Patent Numbers 4,313,734 and 4,373,932. The preparation and use of non-metallic colloids, such as colloidal selenium particles, are disclosed in co-owned and copending Australian Patent Application No. 18826/88, U.S. Patent Application Serial No. 072,084, filed July 9, 1987, which is incorporated by reference herein.

Organic polymer latex particles for use as labels are disclosed in co-owned and copending U.S. Patent Application Serial No. 248,858, filed September 23, 1988, which is incorporated by reference herein. The selection of a particular label is not critical, so long as the label is capable of generating a detectable signal either by itself or in conjunction with one or more additional signal producing substances.

The term "signal producing component" refers to any substance capable of reacting with another assay reagent or the analyte to produce a reaction product or signal that indicates the presence of the analyte and that is detectable by visual or instrumental means. "Signal production system", as used herein, refers to the group of assay reagents that are needed to produce the desired reaction product or signal. For example, one or more signal producing components can be used to react with a label and generate the detectable signal, i.e., when the



label is an enzyme, amplification of the detectable signal is obtained by reacting the enzyme with one or more substrates or additional enzymes to produce a detectable reaction product.

The term "capture binding member" refers to a specific binding member which can bind directly or indirectly to the analyte or indicator reagent and which is bound or is capable of being bound to a solid phase, or is capable of being precipitated, such that the capture binding member can be separated from the test sample and other assay reagents.

The term "capture reagent" refers to a capture binding member which is directly or indirectly attached to a solid phase material to enable the separation of the capture binding member, and analyte or indicator reagent that is bound thereto, from unbound analyte and assay reagents. Typically, the attachment of the capture binding member to the solid phase material is substantially irreversible and can include covalent mechanisms. A capture reagent in which a capture binding member is indirectly attached to a solid phase can be produced by reacting a coupling agent of the instant invention with both the solid phase material and the capture reagent; the product of such a reaction is an example of a "conjugate". In an agglutination assay, the capture binding member of the capture reagent can be bound to a soluble carrier material such as bovine serum albumin.

In producing a capture reagent to be used in an assay, once the capture binding member, e.g., analyte specific antibody, is immobilized upon the solid phase, the remaining surface area of the solid phase is generally blocked with a suitable protein solution, such as bovine serum albumin, to prevent non-specific binding of protein to the support. The solid support is then washed with an appropriate solution to remove any excess blocking solution and/or unbound capture binding member.

Once complex formation occurs between the assay components, the solid phase can be used as a separation mechanism. For example, the reaction mixture can be contacted with the solid phase material, and the solid phase material retains the newly formed reaction complex(es). Alternative methods can be used to perform this separation step, such as using a solid phase which itself binds to the capture binding member; affixing to the solid phase a binding member that is specific for the capture binding member; or affixing to the solid phase a reactive agent, such as a charged substance, which will attract and bind an oppositely charged substance that has been bound to the capture binding member, as disclosed in co-owned and copending ~~U.S. Patent Application Serial No. 150,278, filed January 29, 1988,~~ <sup>Australian Patent Application No. 28660/89,</sup> which is incorporated by reference herein. Either the binding member that is specific for the capture binding member or the reactive agent (e.g., a charged substance) can be bound to or chemically reacted with a coupling agent according to the invention which is also bound to or chemically reacted with the solid phase material; these are also examples of conjugates.

Assay devices can have many configurations, several of which are dependent upon the material chosen for the solid phase. The term "solid phase material" refers to any suitable chromatographic, fibrous, porous or capillary material or other conventional solid material, well-known to those skilled-in-the-art for use in immobilizing specific binding members. Solid



**SUBSTITUTE SHEET**



phase materials can include a fiberglass, cellulose or nylon pad for use in a flow-through assay device having one or more layers containing one or more of the assay reagents; a dipstick for a dip and read assay; a test strip for chromatographic (e.g., paper or glass fiber) or thin layer chromatographic (e.g., nitrocellulose) techniques in which one or all of the reagents are contained in separate zones of a single strip of solid phase material; or an absorbent material well known to those skilled-in-the-art. The solid phase material can also include, without limitation, polyacrylamide beads, polystyrene beads or tubes, magnetic beads, a microtitre plate with one or more reaction wells, microparticles or a glass or plastic test tube.

Natural, synthetic or naturally occurring materials that are synthetically modified, can be used as a solid phase material including polysaccharides, e.g., cellulose materials including paper, cellulose and cellulose derivatives such as cellulose acetate, nitrocellulose and cellulose acetate/nitrate; silica; fiberglass; inorganic materials such as deactivated alumina, diatomaceous earth or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride-propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon); porous gels such as silica gel, agarose, dextran and gelatin; polymeric films such as polyacrylamide; magnetic particles; microtitre plates; polystyrene tubes; protein binding membranes; Sephadex (Pharmacia Fine Chemicals, Inc., Piscataway, N.J.); Trisacryl (Pointet-Girard, France); silicon particles; porous fibrous matrixes; and the like. The solid phase material should have a reasonable inherent strength or strength can be provided by means of a support, and it should not interfere with the production of a detectable signal.

When the specific binding member of the capture reagent is affixed to microparticles, those particles can be retained in a column, suspended in a mixture of soluble reagents and test sample, or retained and immobilized by another solid phase base material. By "retained and immobilized" is meant that the particles, associated with the solid phase base material, are not capable of substantial movement to positions elsewhere within that material. The size of the particles is not critical, although it is preferred that the average diameter be smaller than the average pore size of the solid phase base material if such is used, and they must be of such a size that they can be suspended in a suitable liquid if they are to be used in an agglutination assay.

The term "ancillary specific binding member" refers to a specific binding member used in addition to the capture binding member and the indicator reagent which becomes a part of the detectable binding complex. One or more ancillary specific binding members can be used in an assay. For example, an ancillary specific binding member can be used in an assay where the capture binding member is capable of binding the ancillary specific binding member which is in turn capable of binding the solid phase.

It will be appreciated by those skilled-in-the-art that the selection of any given label, ancillary binding member or solid phase material is generally not critical to the present invention. The materials are chosen to optimize the results provided by the chosen assay configuration.

It has been disclosed, European Patent Application 0 221 505, published May 13, 1987, that immunogens suitable for intravenous administration can be produced by incubation with pepsin immobilized on a hydrophilic gel containing amino groups by a dicarboxylic acid disuccinimidyl ester. The disuccinimidyl ester is disclosed as having a succinimidyl group at each end of a chain having the structure


5



where R is a straight or branched chain alkylene radical having from 1 to 20 carbon atoms. The application specifically discloses only one such compound: adipic acid disuccinimidyl ester where R, above, is a 10 straight chain alkylene group having 4 carbon atoms.

Various bifunctional coupling agents are commercially available, for example from Pierce, exemplary ones being disclosed in a catalog published by that company. Disuccinimidyl suberate and ethylene glycolbis(succinimidylsuccinate) are examples of such coupling agents disclosed in the catalog. In the latter compound, R in the foregoing formula is

15



Cobalamins have the general structure shown in Fig. 1 of the attached drawings. While cobalamins have 20 sometimes been referred to as vitamin B12, there are actually several different types of cobalamins which differ from each other by the R substituent shown in the Figure 1 structure: cyanocobalamin (R=cyano), hydroxycobalamin (R=hydroxy), aquacobalamin (R=H<sub>2</sub>O), nitrocobalamin (R=NO<sub>2</sub>), 5' deoxyadenosylcobalamin (R=5' deoxyadenosyl), and methylcobalamin (R=methyl). Each of these cobalamins is considered generally to be a vitamin B12: cyanocobalamin (vitamin B12), hydroxycobalamin 25 (vitamin B12a), aquacobalamin (vitamin B12b), nitrocobalamin (vitamin B12c), 5' deoxyadenosylcobalamin (coenzyme B12), methylcobalamin (methyl B12). The various cobalamins have similar metabolic activity. Cyanocobalamin, however, is more stable than the others. The cobalamins are involved in many metabolic functions and are essential for normal growth and nutrition, hematopoiesis, production of all epithelial cells, and maintenance of myelin throughout the nervous system.

30 A deficiency in vitamin B12 manifests itself in ineffective hematopoiesis, inadequate myelin synthesis, inadequate maintenance of the epithelial cells of the alimentary tract, and generalized anemia. However, except for inadequate myelin synthesis, these symptoms are common to many megaloblastic anemias, regardless of cause.

To pinpoint the cause of such anemias, it is necessary to test for vitamin B12 deficiencies. There are 35 a variety of different assays for vitamin B12: colorimetric, spectroscopic, fluorometric and radioactive isotope. The most common employs a cobalt 57 radioactive isotope in lieu of the cobalt in the corrin nucleus of the vitamin B12 molecule. The radioactively labelled molecule and B12 intrinsic factor are added to a sample containing B12, and the radioactively labelled B12 and the B12 in the sample compete

5/1

for binding sites on B12 intrinsic factor. The B12 intrinsic factor is associated with a solid phase, so the amount of radioactivity on the solid phase or in the

sample will be proportional to the amount of B12 in the original sample. The current radioassays have obvious disadvantages inasmuch as they involve the handling, storage, and disposal of radioactive materials. Furthermore, detection can be slow.

Enzyme linked competitive binding assays have been proposed (see Bachas, *Biotechnics*, vol. 4, no. 1, p. 42 et seq. (1986)) for vitamin B12. However, the sensitivity of the assay was reported to be 1355 pg/ml while the normal range for vitamin B12 in human serum is from 150-900 pg/ml. Clearly, such an assay cannot be used to test vitamin B12 deficiency since it reportedly cannot even detect vitamin B12 at normal ranges in human serum.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- 10 Fig. 1 is a formula showing the general structure of cobalamins.  
Fig. 2 is a formula showing the structure of a preferred family of compounds according to the invention.  
Fig. 3 is a formula showing the structure of preferred endgroups in the family of compounds of Fig. 2.  
Fig. 4 is a formula showing the structure of a "red fraction" whose preparation is described herein, and is named "CARBOXYLATED B-12".
- 15 Fig. 5 is a plot of enzyme assay determinations of B12 against "BIO-RAD QUANTIPHASE" determinations of B12 in the same samples.  
Fig. 6 is a curve showing instrument readings as a function of cyanocobalamin concentration in standard solutions prepared as described herein.  
Fig. 7 is a formula for a family of active esters, one of which is produced as an intermediate in the
- 20 procedure described herein as Example 1.  
Fig. 8 is a formula showing the structure of a group by which B12 molecules are linked to alkaline phosphatase molecules in a B12/alkaline phosphatase conjugate produced as described in Example 2 hereof.  
Fig. 9 is a formula showing the structure of other preferred endgroups in compounds of the instant invention.
- 25 Fig. 10 is a formula showing the structure of a second preferred family of compounds according to the invention.  
Fig. 11 is a formula showing another structure of preferred endgroups in compounds of the instant invention.  
Fig. 12 is a formula showing the structure of another preferred family of compounds according to the
- 30 invention.  
Fig. 13 is a formula showing the structure of still another preferred family of compounds according to the invention.  
Fig. 14 is a formula showing the structure of intermediates from which compounds having the structure of Fig. 13 can be produced.

35

## BRIEF DESCRIPTION OF THE PRESENT INVENTION


The instant invention is based upon the discovery of a disuccinimidyl compound which is an 18 atom homobifunctional linker having the structure of Fig. 2 of the drawings, where Z has the structure of Fig. 3. The invention is also based upon the further discovery that the sensitivity of an immunoassay for vitamin B12 is unexpectedly increased when a conjugate of intrinsic factor linked to microparticles by the foregoing compound is used in conducting the assay.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention will be more fully understood from the following examples, which constitute the best modes presently contemplated by the inventors. It is to be understood, however, that the examples are presented solely for the purpose of illustration, and are not to be construed as limiting.

As used herein, and in the appended claims, the terms "percent" and "parts" refer to percent and parts by weight, unless otherwise indicated; g means gram or grams; mg means milligram or milligrams; ng means nanogram or nanograms; pg means picogram or picograms; cm means centimeter or centimeters; mm means millimeter or millimeters; L means liter or liters;  $\mu$ L means microliter or microliters;  $\%$  means mole percent, and equals 100 times the number of moles of the constituent designated in a composition divided by the total number of moles in the composition;  $\%$  means percent by volume;  $\%$  means weight per unit of volume, and is in terms of g/L; M means molar and equals the number of gram moles of a solute in one liter of a solution;  $\mu$ M means micromolar and equals the number of microgram moles in one liter of a solution; mM means millimolar and equals the number of milligram moles of a solute in one liter of a solution; N means normal, and equals the number of gram equivalents of a solute in one liter of solution; and  $\mu$ N means micronormal and equals the number of microgram equivalents of a solute in one liter of solution. All temperatures are in  $^{\circ}$ C., unless otherwise indicated.

Example 1 describes the production of the 18 atom homobifunctional linker having the structure of Fig. 2. Example 2 describes the use of the 18 atom homobifunctional linker to bind alkaline phosphatase to "B12 AMINE", a compound having the structure of Fig. 4 of the attached drawings, except that the substituent attached to the 13 carbon in the C ring has the structure



The production of the B12 AMINE is described below, as an introduction to Examples 1 and 2.

## SYNTHESIS OF B12 AMINE

The B12 AMINE to which reference is made above was produced by acid hydrolyzing 2.2 g cyanocobalamin, isolating the monocarboxylic acids which were produced, separating one of the acids, and coupling the separated acid to 1,6-diamino hexane. The cyanocobalamin was added to 300 mL 0.8 M phosphoric acid and heated for six hours at 70 $^{\circ}$  in the dark under a nitrogen blanket. The reaction mixture was applied to a washed ion exchange resin packed in a column; unbound derivatives were eluted; and the bound B12 acids were eluted with methanol

and concentrated by rotary evaporation. The ion exchange resin used is one that is available under the trade designation AMBERLITE XAD-2. The individual B12 acids were then separated on a DE-52 Cellulose column, washed with NaOH, HCl, NaOAc, and equilibrated to pH 5.0 with deionized water. The sample was then added to a 4 x 75 cm column, and slowly eluted. After two days, a single red band containing 5 unreactive corrinoid was removed with distilled water. The B12 monoacids were eluted with 0.05 percent acetic acid. Three peaks were eluted in 36 hours. Each band was collected and concentrated by rotary evaporation. Fractions which contained red material were pooled, while orange-yellow fractions were discarded. A radioassay was used to test the red fractions for reactivity. Mass spectroscopy, C13 NMR and HPLC were used to characterize the red fractions; they were found to have the structure of Fig. 4 of the 10 attached drawings ("MONOCARBOXYLATED B12"); that is, they were carboxylated in position 13 on the C ring.

The B12 AMINE was then produced from 63 mg MONOCARBOXYLATED B12, 0.2554 g 1,6-hexyl diamine and 88.8 mg 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide ("EDAC"). The MONOCARBOXYLATED B12 and the 1,6-hexyl diamine were dissolved in 13 mL distilled water; the 15 pH of the solution was adjusted to 6.0 with 1N HCl; the EDAC was added; and the reaction mixture was stirred for about 16 hours under a nitrogen blanket [Tetsuo Toraya, *J. Biol. Chem.*, 255; 3520-3525 (1980)]. The reaction mixture was concentrated by rotary evaporation and purified by HPLC [Tetsuo Toraya, *Biochem.*, 18:417-426 (1979)]. The B12 AMINE was purified on a C-18 (Magnum 9) column using a solvent system composed of 20 % methanol and 80 % 1 percent aqueous acetic acid at an initial flow rate 20 of 4 ml per minute; after 80 minutes the flow rate was increased to 6 ml per minute. The product was identified as B12 AMINE.

#### EXAMPLE 1

##### Synthesis of the 18 Atom Homobifunctional Linker

###### (A) Synthesis of ester intermediate

25 A disuccinimidyl ester intermediate was first produced from 8.16 g N-hydroxysuccinimide dissolved in 200 mL dimethylformamide, 7.17 g triethylamine and 5.0 g succinyl chloride. The triethylamine was added to the dimethylformamide solution under a nitrogen blanket. Stirring was commenced and was continued while the succinyl chloride was added slowly and for eight hours after the addition was complete. The precipitate which formed was separated from the reaction mixture by filtration, and was dried under 30 high vacuum, yielding crude product which was triturated with 50 ml chloroform and dried in an argon stream under high vacuum, yielding 8.52 g pure white powder which was identified as the disuccinimidyl ester intermediate, a compound which has the structure of Fig. 7 of the attached drawings where Z has the structure of Fig 3.

###### (B) Synthesis of linker

35 The 18 atom homobifunctional linker was then synthesized from 5.0 g disuccinimidyl ester intermediate dissolved in 150 ml dry dimethylformamide, 4.20 g of 6-aminocaproic acid and 6.93 g of dicyclohexylcarbodiimide. The 6-aminocaproic acid was added to the

dimethylformamide solution, and the resulting reaction mixture was stirred under a nitrogen blanket for three hours at room temperature of about 22°. The dicyclohexylcarbodiimide was then added, and the reaction mixture was stirred under a nitrogen blanket for about 16 hours at room temperature. Dicyclohexyl urea precipitate which had formed was then separated from the reaction mixture by filtration, and 5 dimethylformamide was evaporated from the filtrate under reduced pressure. Trituration with ether followed by drying under high vacuum yielded 7.94 g 18 atom homobifunctional linker.

#### EXAMPLE 2

##### Production of B12:Alkaline Phosphatase Conjugate

A conjugate was prepared from

- 10 (1) 0.173 mL 0.82 mM B12 AMINE solution in 50 % dimethylformamide and dimethylsulfoxide,  
 (2) 0.142 mL 1.88 mM 18 atom homobifunctional linker solution in 50 % dimethylformamide and dimethylsulfoxide,  
 (3) 1.0 mL alkaline phosphatase (Boehringer Mannheim; 10 mg/mL) that had been  
 15 dialyzed in 50 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM zinc chloride, and  
 (4) 0.0749 mL 50 % dimethyl-formamide and dimethylsulfoxide.

The B12 AMINE solution, the 18 atom homobifunctional linker solution and the 50 % dimethylformamide and dimethylsulfoxide were mixed in a glass vial and allowed to react at room temperature of about 22°  
 20 for 30 minutes. The reaction mixture was then added to the dialyzed alkaline phosphatase, mixed gently, and allowed to stand for about 20 hours at 4°. The reaction mixture was separated on Sephadex G 50-100 (1.2 x 44 cm) using 50 mM tris(hydroxymethyl)-aminomethane ("TRIS"; pH 7.4) in deionized water which additionally contained 1.0 mg mole per liter magnesium chloride and 0.10 mg mole per liter zinc chloride. The appropriate fractions were pooled and dialyzed against 1000 ml TRIS (pH 7.4) in deionized water  
 25 which additionally contained 1.0 mg mole per liter magnesium chloride and 0.10 mg mole per liter zinc chloride. The product was a B12/alkaline phosphatase conjugate in which B12 molecules were linked to alkaline phosphatase molecules by groups which had the structure of Fig. 8 of the attached drawings, the Z groups of Fig. 2 having been displaced during preparation of the conjugate. The B12/alkaline phosphatase conjugate was then diluted to a desired concentration to produce an "Enzyme-B12 Conjugate Working  
 30 Solution".

Example 3, below, describes the use of the linker produced as described in Example 1 to bind purified intrinsic factor to treated microparticles. The preparation of purified intrinsic factor and of the treated microparticles to which the 18 atom homobifunctional linker of Example 1 bound the purified intrinsic factor are described below as an introduction to Example 3.

### PREPARATION OF PURIFIED INTRINSIC FACTOR

About 40 pig duodenum were washed and cut into small pieces. The pieces were blended, acidified with perchloric acid to pH 1.0, and mixed for one hour. The large pieces were removed by centrifugation, and the supernatant was neutralized with 5N KOH solution in deionized water. After about 16 hours at 4°C a precipitate had formed. The top 90 percent of the supernatant was aspirated and filtered through celite to remove lipid. The intrinsic factor in the clear filtrate was purified by affinity chromatography on an affinity column having a mixture of e and d B12 carboxyl derivatives ligated to cyanogen bromide sepharose 4b.

The non-specifically bound protein was removed by washing the column with 4 M NaCl solution in deionized water, and then with 50 mM potassium phosphate buffer in deionized water. The intrinsic factor was eluted with 3.8 M Guanidine-HCl. The initial intrinsic factor fraction eluted from the column contained the intrinsic factor selected for use in the assays of this invention; later fractions yielded assays with lesser performance. The intrinsic factor in the desired fractions was tested for the presence of R proteins which bind many corrinoid ring-containing compounds (i.e. cobinamides) including but not limited to cobalamins. Once the intrinsic factor was tested (by radioassay using B12 cobalt 57) to contain less than 0.004 percent cross-reactivity with cobinamides, the intrinsic factor was exhaustively dialyzed with several changes of deionized water. The first fraction, affinity purified in this manner ("Purified Intrinsic Factor"), has been found to contain proteins of which at least 85% bind cobalamins. Less than about 85 percent functional purity was found to yield assays with impaired sensitivity.

20

### TREATMENT OF MICROPARTICLES

A 0.5 g portion of a resin which is commercially available under the trade designation BIORAD BIO-REX MSX 501 (D) was washed several times with deionized water. A 1 mL portion of amino microparticles (SERADYNE, average diameter 0.26  $\mu\text{m}$ ; average parking area 390 angstroms<sup>2</sup> per amine group) and about 1 mL deionized water were then mixed with the resin, and the mixture was rotated for one hour at room temperature. The resin was allowed to settle, and the microparticles were decanted. Another 1 mL addition of deionized water was made to the resin and, after mixing, the microparticles were again decanted. The water rinse, mix and decant steps were repeated twice, and deionized water was added to the decanted microparticles to bring the microparticle solids content to 7.5 percent ("Treated Microparticles").

#### EXAMPLE 3

#### 30 Microparticle Functionalization

A microparticle/intrinsic factor conjugate was produced from 300  $\mu\text{L}$  Treated Microparticles, 600  $\mu\text{L}$  Purified Intrinsic Factor solution which contained 38  $\mu\text{g}$  per mL intrinsic factor and 33  $\mu\text{L}$  of a dimethylformamide solution which contained 1.0 mg per mL 18 atom homobifunctional linker produced as described in Example 1 (B). The microparticles and the dimethylformamide solution of the 18 atom homobifunctional were charged to a small plastic vial, and the vial was rotated for 30 minutes; the intrinsic factor was then charged, and the vial was rotated at room temperature of about 22°C for 16 hours, to produce the intrinsic



factor factor/microparticle conjugate. Before use, the conjugate was washed twice with a 0.05 percent solution in deionized water of a surfactant that is commercially available under the trade designation TWEEN 20 and twice with a 0.05 M solution of TRIS (pH 7.4) in deionized water. An "Intrinsic Factor-Microparticle Conjugate, 18 Atom Linker" was then produced by diluting one part by volume of the 5 intrinsic factor/microparticle conjugate with 250 parts by volume of a particle diluent which was a 0.8 M TRIS solution (pH 7.4) in deionized water which also contained 1 percent bovine serum albumen, 0.1 percent  $\text{NaN}_3$ , 0.01 percent of a surfactant that is commercially available under the trade designation TWEEN 20, and 0.4 g mole per liter sucrose.

Examples 4 and 5 describe the derivation of a standard curve showing signal as a function of 10 cyanocobalamin concentration in standard solutions when enzyme linked B12 assays were performed on a fully automated machine (ABBOTT IMx® analyzer) and the use of the standard curve to assay unknown samples for cobalamin. The Enzyme-B12 Conjugate Working Solution, the Intrinsic Factor-Microparticle Working Conjugate, 18 Atom Linker, and a "Working Substrate Indicator" were used in carrying out the procedures of Examples 4 and 5. The Working Substrate Indicator was a 100 mM solution of 2-amino-2-15 methyl-1-propanol (pH 10.3) which also contained 1 mg mole per L  $\text{MgCl}_2$ , 4 mg moles per L tetramisole, 1.2 mg moles per L 4-methylumbelliferone-phosphate ("MUP") and 0.1 percent  $\text{NaN}_3$ .

#### ASSAY PROTOCOL USED IN PERFORMING ENZYME LINKED B12 ASSAY

A standard or a serum sample was denatured at 34° for 8 minutes by adding cobinamide, a thiol reagent such as x-monothioglycerol and NaOH until the standard or sample contained 0.3 g equivalent per L 20 sodium hydroxide (the purpose of this step was to dissociate B12 from serum binding proteins). The denatured solution was then neutralized with the Intrinsic Factor-Microparticle Working Conjugate, and the neutralized composition was incubated for 15 minutes at room temperature. The incubated composition was then deposited on a separation material surface, which was an IMx® disposable reaction cell sold by Abbott Laboratories, North Chicago, Illinois; B12 bound to intrinsic factor conjugated to the microparticles 25 was retained on the separation material surface, while B12 that was not so bound could be washed away. The separation material surface was then washed with a 50 mM TRIS (pH 7.4) solution in deionized water to free it of unbound B12. A 50  $\mu\text{L}$  portion of the Enzyme-B12 Conjugate Working Solution was added to the separation material surface to bind free intrinsic factor sites. The separation material surface was again washed with the 50 mM TRIS (pH 7.4) solution in deionized water, after which a 50  $\mu\text{L}$  portion of 30 the Working Substrate Indicator was added and the separation material surface was excited with radiation having a wavelength of 362 nm. MUP is hydrolyzed by alkaline phosphatase, releasing 4-methylumbelliferone, which fluoresces when excited by radiation having a wavelength of 362 nm, emitting radiation having a wavelength of 448 nm. The reading given by the IMx® instrument was the initial intensity per unit of time of the emission at a wavelength of 448 nm when the alkaline phosphatase 35 substrate indicator was

added to the separation material surface. The readings from patient serum samples were compared with the curve to determine B12 content.

#### EXAMPLE 4

The foregoing protocol was used to determine signal as a function of cyanocobalamin concentration in 5 standards prepared by diluting USP cyanocobalamin in 50 mM TRIS solution (pH 7.4) in deionized water which also contained 1 percent bovine serum albumen, 0.2 percent  $\text{NaN}_3$ , 100 mg moles per L of NaCl, 1.0 mg mole per L of  $\text{MgCl}_2$  and 0.1 mg mole per L  $\text{ZnCl}_2$ . The standards contained 0, 62.5, 125, 250, 1000, and 2000 pg/mL cyanocobalamin. The IMx® instrument readings from the standard samples gave data for a curve showing readings as a function of B12 content.

#### 10 EXAMPLE 5

The foregoing protocol was used to determine the signal from various patient samples. It has been found that the assay is capable of detecting as little as 38 pg per mL B12. Patient serum samples (n = 136) were assayed as described above, and in radioassay apparatus that is commercially available from Becton Dickinson (Orangeberg, New York) under the designation SimulTrac™. A correlation curve was calculated 15 from the data from the two test methods; the slope of the curve was found to be 1.01, while the correlation coefficient (R) was 0.99.

Example 6, below, describes the synthesis of N-hydroxysuccinimidyltricaproamidocyclohexylmethylmaleimide from N-(carbocyclohexylmethyl) maleimide, 6-aminocaproic acid, dicyclohexylcarbodiimide and N-hydroxysuccinimide, and the synthesis from N-hydroxy- 20 succinimidyltricaproamidocyclohexylmethylmaleimide of a 68 atom homobifunctional linker having the structure of Fig. 13 of the attached drawings where Z' has the structure of Fig. 11, and  $\text{C}_6\text{H}_{10}$  is 1,4-cyclohexylene.

#### EXAMPLE 6

##### (A) Preparation of N-hydroxysuccinimidylcaproamidocyclohexylmethylmaleimide

25 An N-hydroxysuccinimidylcaproamidocyclohexylmethylmaleimide, a compound having the structure of Fig. 14 of the attached drawings where Z has the structure of Fig. 3, Z' has the structure of Fig. 11, n is 1, and  $\text{C}_6\text{H}_{10}$  is 1,4-cyclohexyl, was first produced from a solution of 100 mg N-(4-carboxycyclohexylmethyl) maleimide in dry dimethylformamide, 39.23 mg 6-aminocaproic acid, 67.8 mg dicyclohexylcarbodiimide and 37.8 mg N-hydroxysuccinimide. The N-(4-carboxycyclohexylmethyl) 30 maleimide was produced from trans-4-(aminomethyl)-cyclohexanecarboxylic acid (Aldrich Chemical Co.) by the method of Yoshitake et al. (*J. Biochem.*, 101:395-399 (1979)). A nitrogen atmosphere was established in a flask above the N-(4-carboxycyclohexylmethyl) maleimide solution, and the 6-aminocaproic acid was added to the flask. The reaction mixture was then stirred under nitrogen at room temperature of about 22° for 16 hours, after which time the dicyclohexylcarbodiimide and the N- 35 hydroxysuccinimide were added to the flask. Stirring at room temperature was continued for an additional 6 hours, after which time dicyclohexylurea which had precipitated was removed from the reaction mixture by filtration, and the dimethylformamide was evaporated under reduced pressure from

the filtrate. A tacky solid which remained was purified by flash chromatography on silica gel (5%, methanol in chloroform), yielding 71 mg N-hydroxysuccinimidylcaproamidocyclohexyl-methylmaleimide, a white solid which has the indicated formula.

(B) Preparation of N-hydroxysuccinimidylcaproamidocyclohexylmethylmaleimide

5 An N-hydroxysuccinimidylcaproamidocyclohexylmethylmaleimide, a compound having the structure of Fig. 14 of the attached drawings where Z has the structure of Fig. 3, Z' has the structure of Fig. 11, n is 2, and C<sub>6</sub>H<sub>10</sub> is 1,4-cyclohexyl, was then produced from a solution of 100 mg N-hydroxysuccinimidylcaproamidocyclohexylmethylmaleimide in 1 ml dry dimethyl-formamide, 29.3 mg 6-aminocaproic acid and 50.7 mg dicyclohexylcarbodiimide. A nitrogen atmosphere was established in a flask  
10 above the N-hydroxysuccinimidylcaproamidocyclohexyl-methylmaleimide solution, and the 6-aminocaproic acid was added to the flask. The reaction mixture was then stirred under nitrogen at room temperature of about 22° for 16 hours, after which time the dicyclohexylcarbodiimide was added to the flask. Stirring at room temperature was continued for an additional 6 hours, after which time dicyclohexylurea which has precipitated was removed from the reaction mixture by filtration, and the dimethylformamide was  
15 evaporated under reduced pressure from the filtrate. A tacky solid which remained was purified by flash chromatography on silica gel (10%, methanol in chloroform), yielding 60 mg of the N-hydroxysuccinimidylcaproamidocyclohexylmethylmaleimide, which has the indicated formula.

(C) Preparation of N-hydroxysuccinimidyltricaproamidocyclohexylmethylmaleimide

An N-hydroxysuccinimidyltricaproamidocyclohexylmethylmaleimide, a compound having the structure  
20 of Fig. 14 of the attached drawings where Z has the structure of Fig. 3, Z' has the structure of Fig. 11, n is 3, and C<sub>6</sub>H<sub>10</sub> is 1,4-cyclohexyl, was then produced from a solution of 100 mg N-hydroxysuccinimidylcaproamidocyclohexylmethylmaleimide in 2 ml dry dimethylformamide, 23.4 mg 6-aminocaproic acid and 40.5 mg dicyclohexylcarbodiimide. A nitrogen atmosphere was established in a flask above the N-hydroxysuccinimidylcaproamido-cyclohexylmethylmaleimide solution, and the 6-  
25 aminocaproic acid was added to the flask. The reaction mixture was then stirred under nitrogen at room temperature of about 22° for 16 hours, after which time the dicyclohexylcarbodiimide was added to the flask. Stirring at room temperature was continued for an additional 6 hours, after which time dicyclohexylurea which had precipitated was removed from the reaction mixture by filtration, and the dimethyl-formamide was evaporated under reduced pressure from the filtrate. A tacky solid which remained  
30 was purified by flash chromatography on silica gel (10%, methanol in chloroform), yielding 60 mg of the N-hydroxysuccinimidyltricaproamidocyclohexylmethylmaleimide, a white solid which has the indicated formula.

(D) Preparation of the 68 atom homobifunctional linker

The 68 atom homobifunctional linker, a compound having the structure of Fig. 13 where Z' has the  
35 structure of Fig. 11 and -C<sub>6</sub>H<sub>10</sub> is 1,4-cyclohexyl, can be produced at room temperature of about 22° from a solution of 0.2342 g 1,6-hexanediamine in 3 mL dry

dimethylformamide and a solution of 2.695 g N-hydroxysuccinimidyltricaproamidocyclohexylmethylmaleimide in 10 mL dry dimethylformamide. The N-hydroxysuccinimidyltricaproamidocyclohexylmethylmaleimide solution is poured rapidly into the hexanediamine solution, with vigorous stirring. Stirring is continued for about two hours, after which time the dimethylformamide is evaporated, 5 and the residue is washed three times with 15 mL portions of a 50% acetone in methanol solvent, and dried under reduced pressure to yield the desired product.

Example 7 describes the use of a 23 atom heterobifunctional linker produced as described in Example 6 (B) to bind purified intrinsic factor to treated microparticles. The preparations of purified intrinsic factor and of the treated microparticles to which the 23 atom heterobifunctional linker of Example 6 (B) bound 10 the purified intrinsic factor are described above, as an introduction to Example 3.

#### EXAMPLE 7

##### Microparticle Functionalization

A microparticle/intrinsic factor conjugate was produced by combining Treated Microparticles, 700  $\mu$ L Purified Intrinsic Factor solution which contained 38  $\mu$ g per mL intrinsic factor and 80  $\mu$ g of the 23 atom 15 heterobifunctional linker produced as described in Example 3 (B) in 17.5 mM triethanolamine buffer (pH 8.0) to produce 1 mL of a solution which contained 0.6 percent of the microparticles. The solution which resulted was mixed for 2 hours in the dark at room temperature of about 22°. After incubation, the particles were pelleted and washed several times in mild detergent /50 mM TRIS buffer solution, homogenized to ensure uniform particle size distribution, and diluted to the desired concentration ("Intrinsic Factor- 20 Microparticle Conjugate, 23 Atom Linker").

#### EXAMPLE 8

The procedure of Example 4 was repeated, except that the Intrinsic Factor-Microparticle Conjugate, 23 Atom Linker was substituted for the 18 Atom Linker. Fig. 6 of the attached drawings is a curve showing instrument readings as a function of B12 content as determined by this procedure. The purified intrinsic 25 factor was conjugated to the microparticles by a chemical moiety which was derived from the 23 atom linker; the moiety had the structure of Fig. 15 of the attached drawings.

#### EXAMPLE 9

The procedure of Example 5 was also repeated, except that the Intrinsic Factor-Microparticle Conjugate, 23 Atom Linker was substituted for the 18 Atom Linker. It was found that the assay was capable of 30 detecting less than 60 pg per mL B12, based on a calculation using two times the standard deviation of multiple runs of the zero standard. Patient serum samples (n = 76) were assayed as described above, and in radioassay apparatus that is commercially available under the designation BIORAD, Quantaphase™ radioassay. The correlation curve, Fig. 5 of the attached drawings, was calculated from the data from the two test methods; the slope of the curve was found to be 1.10, while the correlation coefficient (R) was 35 0.99.

Various other linkers according to the invention have been produced by the procedures described above and modifications thereof. Representative ones of those preparations are described in the following Examples.

**EXAMPLE 10**

5 A 22 atom bis (hydrazide) homobifunctional linker was produced from 0.50 g 18 atom bifunctional linker produced as described in Example 1 (B) dissolved in 5 ml dry methanol and 0.14 g hydrazine hydrate dissolved in 2 ml methanol. The hydrazine hydrate solution was poured into a flask and cooled to 0°; magnetic stirring was commenced, and was continued during the slow addition of the linker solution and for 30 minutes after the addition was complete. The contents of the flask were kept at 0° during the addition  
10 of the linker solution and were allowed to warm to room temperature of about 22° during the following 30 minutes. The reaction solution was then filtered through a sintered glass funnel and chromatographed on a silica gel column, using a gradient of 0.5 to 20% methanol in chloroform. The fractions which contained the bis (hydrazide) homobifunctional linker were collected and dried, yielding 0.21 g of the desired compound, which had the formula of Fig. 2 of the attached drawings where Z is H<sub>2</sub>NHN. The compound  
15 was identified by NMR.

**EXAMPLE 11**

A bis (iodoacetyl) 26 atom homobifunctional linker was produced at room temperature of about 22° from 3 mL of a methanol solution which contained 0.15 g bis (hydrazide) homobifunctional linker (Example 10) and 3 mL of a methanol solution which contained 0.15 g iodoacetic acid N-hydroxysuccinimide ester. A  
20 flask which contained the bis (hydrazide) homobifunctional linker solution was placed in the dark, and stirring of the solution was commenced. The iodoacetic acid N-hydroxysuccinimide ester solution was added slowly to the flask; stirring was continued during the addition and for about 1 hour after the addition was complete. The solution was then chromatographed on a short silica gel column using 0.5 to 10% methanol in chloroform. The solvent was then evaporated from the fractions which contained the desired  
25 product, leaving 0.06 g bis (iodoacetyl) 26 atom homobifunctional linker, which had the structure of Fig. 2 of the attached drawings where Z has the structure of Fig. 9.

**EXAMPLE 12**

A bis (maleimide) 22 atom homobifunctional linker was produced at room temperature from a solution of 0.668 g succinimidyl 4-(N-maleimidylmethyl)cyclohexane-1-carboxylate dissolved in 5 mL dry  
30 dimethylformamide, 0.200 g fresh triethylamine and 0.060 g ethylenediamine. The succinimidyl 4-(N-maleimidylmethyl) cyclohexane-1-carboxylate solution was charged to a 100 mL round bottom flask. Stirring was commenced, and was continued during the addition of the triethylamine and of the ethylenediamine and for one hour after the addition was complete (a copious precipitate formed two minutes after the addition of the triethylamine and of the ethylenediamine was complete). The precipitate was then  
35 recovered by filtration, washed with water/methanol and dried. The product was identified by NMR as the bis (maleimide) 22 atom

homobifunctional linker having the structure of Fig. 10 of the attached drawings where Z' has the structure of Fig. 11, and C<sub>6</sub>H<sub>10</sub> is 1,4-cyclohexylene.

Example 13 describes the synthesis of a homobifunctional linker according to the invention which has the structure of Fig. 12 of the attached drawings where n is 2 and Z has the structure of Fig. 3.

#### 5 EXAMPLE 13

The homobifunctional linker having the structure of Fig. 12 can be synthesized from 13.6 g 18 atom homobifunctional linker [Example 1 (B)] dissolved in 410 ml dry dimethylformamide, 6.65 g 6-aminocaproic acid and 10.4 g dicyclohexylcarbodiimide. The 6-aminocaproic acid is added to the dimethylformamide solution, and the resulting reaction mixture is stirred under a nitrogen blanket for three 10 hours at room temperature of about 22°. The dicyclohexyl-carbodiimide is then added, and the reaction mixture is stirred under a nitrogen blanket for about 16 hours at room temperature. Dicyclohexyl urea precipitate which forms is then separated from the reaction mixture by filtration, and dimethylformamide is evaporated from the filtrate under reduced pressure. Trituration with ether followed by drying under high vacuum yields the indicated homobifunctional linker.

15 It will be appreciated from the foregoing examples that various changes and modifications can be made from the specific details of the invention as disclosed in the foregoing examples without departing from the spirit and scope thereof. For example, while the synthesis of an 18 atom homobifunctional linker is described in Example 1 (B) from a disuccinimidyl ester intermediate and 6-aminocaproic acid, an equivalent amount of various other aminoacids can be substituted for the 6-aminocaproic acid to produce 20 other linkers having different numbers of atoms. Examples of aminoacids that can be so substituted include glycine, 3-amino-n-propionic acid, 4-amino-n-butyric acid, 5-amino-n-valeric acid, 7-amino-n-heptic acid, 8-amino-n-caprylic acid, 9-amino-n-nonylic acid and 10-amino-n-capric acid. Similarly, two different ones of the aminoacids can be reacted with the disuccinimidyl ester intermediate to produce linkers containing two different aminoalkyl groups.


25 In addition, the procedures of parts (A), (B) and (C) of Example 6 can be carried out using equivalent amounts of any of the amino acids named in the preceding paragraph to produce other N-hydroxysuccinimidyltriamidocyclohexylmethylmaleimides which can then be converted to homobifunctional linkers by the procedure of Example 6 (D), and the N-hydroxy-succinimidyldiamidocyclohexylmethylmaleimides of Example 6 (B) can also be converted to 30 homobifunctional linkers by the procedure of Example 6 (D). Similarly, other diamines can be substituted for the 1,6-hexanediamine in the procedure of Example 6 (D) to produce other linkers. Examples of diamines that can be so substituted include ones having the formula



where x is an integer from 2 to 10.


35

Accordingly, it will be appreciated that the instant invention, in a first aspect, is a coupling agent having the formula




where

5  $Z_1$  and  $Z_2$  are the same when they are



$Z_1$  and  $Z_2$  are the same or different when they are




$k$ ,  $m$  and  $n$  are integers from 1 to 10;

10  $X$  is an alkylene group, a cycloalkylene group, an alkylcycloalkylene group, a bivalent carbocyclic aromatic group, or an aminoalkylene group;

$R$  and  $R'$  can be the same or different, and each is a substituted or unsubstituted  $C_1$ - $C_{10}$  straight chain aminoalkylene; and


$R''$  is a  $C_2$ - $C_{10}$  alkylene or a  $C_5$ - $C_{20}$  cycloalkylene or alkylcycloalkylene.

15 In a second aspect, the invention is a coupling agent having the formula



where

$Z_3$  and  $Z_4$  are the same or different and are



$k$  and  $m$  are integers from 0 to 10;

$n$  is an integer from 1 to 10;




X is an alkylene group, a cycloalkylene group, an alkyl cycloalkylene group, a bivalent carbocyclic aromatic group;

R and R' can be the same or different, and each is a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> straight chain aminoalkylene; and

5 R" is a C<sub>2</sub>-C<sub>10</sub> alkylene or a C<sub>5</sub>-C<sub>20</sub> cycloalkylene or alkylcycloalkylene.

In a third aspect, the invention is a coupling agent having the formula




where

x and n are integers from 1 to 10;

10 y is an integer from 2 to 10; and


Z<sub>5</sub> and Z<sub>6</sub> are the same or different and are






The claims defining the invention are as follows:

1. A coupling agent having the formula




where

- 5  $Z_1$  and  $Z_2$  are the same when they are



$Z_1$  and  $Z_2$  are the same or different when they are




$k$ ,  $m$  and  $n$  are integers from 1 to 10;

- 10  $X$  is an alkylene group, a cycloalkylene group, an alkylcycloalkylene group, a bivalent carbocyclic aromatic group, or an aminoalkylene group;

$R$  and  $R'$  can be the same or different, and each is a substituted or unsubstituted  $C_1$ - $C_{10}$  straight chain aminoalkylene; and


$R''$  is a  $C_2$ - $C_{10}$  alkylene or a  $C_5$ - $C_{20}$  cycloalkylene or alkylcycloalkylene.

- 15 2. A coupling agent having the formula



where

$Z_3$  and  $Z_4$  are the same or different and are



$k$  and  $m$  are integers from 0 to 10;

$n$  is an integer from 1 to 10;




X is an alkylene group, a cycloalkylene group, an alkyl cycloalkylene group, a bivalent carbocyclic aromatic group;

R and R' can be the same or different, and each is a substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> straight chain aminoalkylene; and

5 R" is a C<sub>2</sub>-C<sub>10</sub> alkylene or a C<sub>5</sub>-C<sub>20</sub> cycloalkylene or alkylcycloalkylene.

3. A coupling agent having the formula




where

x and n are integers from 1 to 10;

10 y is an integer from 2 to 10; and


Z<sub>5</sub> and Z<sub>6</sub> are the same or different and are



wherein R" is a C<sub>2</sub>-C<sub>10</sub> alkylene or a C<sub>5</sub>-C<sub>20</sub> cycloalkylene or alkylcycloalkylene.

15 4. A coupling agent according to claim 1 where

Z<sub>1</sub> and Z<sub>2</sub> are




R and R' are the same and are C<sub>5</sub> aminoalkylene;

X is -CH<sub>2</sub>-;

20 m and k are one; and

n is two.


5. A coupling agent according to claim 2 which is



where

Z<sub>3</sub> and Z<sub>4</sub> are the same and are






x is an integer from 1 to 10;


y is an integer from 0 to 10; and

n is an integer from 2 to 10.


- 5 6. A coupling agent according to claim 5 which is



7. A coupling agent according to claim 4 which is




8. A coupling agent according to claim 4 which is




10


9. A coupling agent according to claim 2 which is




where Z<sub>3</sub> and Z<sub>4</sub> are the same and are



10. A coupling agent according to claim 5 which is



where  $Z_3$  and  $Z_4$  are the same and are



5 11. A conjugate in which microparticles are conjugated to intrinsic factor purified by separation of R-proteins therefrom to such an extent that the purified material contains less than 0.004 percent cross reactivity with cobinamides by a moiety derived from a coupling agent as claimed in any one of claims 1-10.

12. A conjugate of microparticles and intrinsic factor as claimed in claim 11  
10 wherein at least 95 percent of the proteins bind cobalamins.

13. A kit for conducting an assay for cobalamins, said kit comprising a conjugate in which microparticles are conjugated to intrinsic factor purified by separation of R-proteins therefrom to such an extent that the purified material contains less than 0.004 percent cross reactivity with cobinamides by a moiety derived from a coupling agent as  
15 claimed in any one of claims 1-10, a conjugate in which an enzyme and a specific binding member for the purified intrinsic factor are conjugated to one another by a moiety derived from a coupling agent as claimed in any one of claims 1-10, and a substrate indicator which reacts with the enzyme to produce a signal or to produce a reaction product which can be caused to produce a signal.

20 14. A kit as claimed in claim 13 wherein the enzyme is alkaline phosphatase and the indicator is MUP.

15. A kit as claimed in claim 14 wherein the specific binding member is B12 AMINE.

25 16. A method for conducting an assay for cobalamins, said method comprising denaturing a test sample, adding to the denatured test sample a conjugate wherein microparticles are conjugated to intrinsic factor purified by separation of R-proteins therefrom to such an extent that the purified material contains less than 0.004 percent cross reactivity with cobinamides by a moiety from a coupling agent as claimed in any one of claims 1-10, incubating the denatured test sample containing the conjugate,  
30 depositing the incubated composition on a separation material which retains the intrinsic factor/microparticle conjugate, washing the separation material surface to remove

unbound B12, adding a conjugate of an enzyme and a specific binding member for the purified intrinsic factor to the separation material to bind free intrinsic factor sites, washing the separation material, adding a substrate indicator which reacts with the enzyme to produce a signal or to produce a reaction product which can be caused to  
5 produce a signal, and measuring the signal produced by reaction between the enzyme and the indicator or causing the product of the reaction between the enzyme and the indicator to produce a signal and measuring the signal.

17. A homobifunctional coupling agent, substantially as hereinbefore described with reference to any one of the Examples.

10

DATED this Fifth Day of August 1994

**Abbott Laboratories**

Patent Attorneys for the Applicant  
**SPRUSON & FERGUSON**

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182







Fig. 1

1/6


2/6




*Fig. 2*




*Fig. 7*



*Fig. 8*



*Fig. 9*



*Fig. 10*

02




Fig. 4



Fig. 5






Fig. 6




5/6


6/6




*Fig. 11*




*Fig. 12*



*Fig. 13*



*Fig. 14*



*Fig. 15*

**I. CLASSIFICATION OF SUBJECT MATTER** In several classification symbols apply. (3) (11)  
 According to International Classification (IPC) or to both National Classification and IPC  
 IPC(5): GOIN 35/567; C07D 207/40, 207/452, 207/46, 207/444; C07C 243 24  
 U.S. Cl: 436/505; 564/151; 548/520, 521, 542, 546, 549

**II. FIELDS SEARCHED**

Minimum Documentation Searched <sup>7</sup>

Classification System	Classification Symbols
U.S.	564/151; 436/505; 548/520, 521, 542, 546, 549

Documentation Searched other than Minimum Documentation  
to the extent that such Documents are included in the Fields Searched <sup>8</sup>

Computer: Chemical Abstracts formula of compound

**III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>**

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X A	J. Chem. Soc. Chem. Commun., Vol. 9, issued May 1986, Brownlee et al., "The Synthesis and Characterization of a Series of Bis-intercalating Bis-anthracyclines," see pages 659-661, especially pages 659-660.	1-5, 15 6-14
X Y	FEBS Letters, Vol. 48, No. 2, issued November 1974, Lutter et al., "The use of a New Series of Cleavable Protein-Crosslinkers on Escherichia Coli Ribosome", see pages 288-292 (see entire document).	1-5, 15 9, 10

- |   |   |
|---|---|
| <p><sup>10</sup> Special categories of cited documents:</p> <ul style="list-style-type: none"> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filing date</li> <li>"L" document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filing date but later than the priority date claimed</li> </ul> | <ul style="list-style-type: none"> <li><sup>11</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li><sup>12</sup> document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</li> <li><sup>13</sup> document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</li> <li><sup>14</sup> document number of the same patent family</li> </ul> |
|---|---|

**IV. CERTIFICATION**

Date of the Actual Completion of the International Search	Date of Making of this International Search Report
---	--

24 January 1992	12 FEB 1992
-----------------	-------------

International Searching Authority	Signature of Authorized Officer
ISA/US	Sam Rosen

FOZ